Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the impact of an antipsychotic medication decision aid and interpersonal and cognitive factors, such as attachment style and motivation, on emerging adults' ability to engage in shared decision making regarding their medications.


Clinical Trial Description

The long-term occupational, social, and economic outcomes associated with psychosis make it an urgent public health problem. Coordinated specialty care (CSC) is now the gold standard for early psychosis, demonstrating positive clinical and functional effects in the short-term, and longer-term reduced hospitalization rates. These services include an array of treatment options, including psychotropic medications, individual psychotherapy, family education, and support, and occupational therapy and supported employment/education. While a shorter period between psychosis onset and receipt of appropriate care is associated with better outcomes, emerging adults often experience significant delays before receiving treatment, and a large percentage disengage from services once they are commenced. Decisional conflict about treatment options (i.e., feeling conflicted about which option to choose) and interpersonal factors such as attachment style and trust in health providers can contribute to decision delay and discontinuance of chosen options. Decision support tools (e.g., decision aids), have been shown to reduce decisional conflict as well as improve service engagement. A requisite step in expanding the array of decision support tools available to emerging adults experiencing early psychosis is to better understand their decision-making ability, capacity, and motivation to engage in decision making and how these relate to their engagement in CSC. It is well recognized that individuals who are being prescribed antipsychotic medications often face decisional conflict about their treatment options. An especially controversial decision is whether individuals should continue taking medication at the same dose or adjust the dose whilst monitoring their symptoms. This dilemma is the result of some uncertainty about the appropriate treatment strategy for long-term management of psychosis. The present project focuses on evaluating the feasibility and effectiveness of the use of a decision aid for making decisions about antipsychotic medication. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04373590
Study type Interventional
Source Temple University
Contact
Status Completed
Phase N/A
Start date February 27, 2019
Completion date August 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06032182 - PSYCHE Cognitive Remediation & Social Recovery Study N/A
Active, not recruiting NCT06192602 - Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis N/A
Recruiting NCT04411225 - Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis Phase 3
Completed NCT04592042 - Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study) Early Phase 1
Active, not recruiting NCT04166019 - Effect of a Peer-led Self-management Program for Recent-onset Psychosis N/A
Recruiting NCT04317807 - R33: Levetiracetam in Early Psychosis Phase 2